Curosurf

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This product helps improve lung function and oxygenation, supporting critical care in neonatal units.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs lack sufficient surfactant, a substance that keeps the air sacs open. By administering Curosurf, healthcare providers aim to replace the missing surfactant, facilitating easier breathing and improving lung function. The therapy is typically administered via endotracheal tube, directly into the lungs.

Curosurf works by reducing surface tension in the lungs, which helps to keep the air sacs open and functional. This can lead to improved oxygenation and reduced breathing efforts in premature infants. The effects are generally observed shortly after administration, supporting the infant's respiratory stability.

Curosurf should be administered by trained healthcare professionals in a controlled medical setting. Proper handling and storage are essential to maintain the product's efficacy. As with any medical intervention, monitoring for any adverse reactions is crucial, and healthcare providers should follow established protocols for administration.

Curosurf is generally used in a controlled medical environment where interactions with other medications are carefully managed. However, it is important to inform healthcare providers about any other medications or treatments the infant is receiving to ensure safety and compatibility.